MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD.
Roberto Mina, MD
Advertisement
an associate professor at the Winship Cancer Institute of Emory University
Articles by Roberto Mina, MD
Roberto Mina, MD, details how in the MajesTEC-9 trial, teclistamab monotherapy boosted PFS and OS in relapsed/refractory multiple myeloma, challenging standardized care.
The results of the phase 3 MajesTEC-9 trial showcase teclistamab's efficacy for patients with relapsed/refractory multiple myeloma, explained Roberto Mina, MD.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on AJMC
1
Michigan Cyclospora Outbreak Surpasses 1500 Cases as Investigation Continues
2
FDA Expands Pembrolizumab-Enfortumab for Muscle-Invasive Bladder Cancer
3
FDA Approves Isatuximab On-Body Injector, Raising Anti-CD38 Competition in Myeloma
4
AI Chatbots Score Below 28% on Colorectal Cancer Questions
5